alexa Should angiotensin II receptor blockers and statins be combined?
Bioinformatics & Systems Biology

Bioinformatics & Systems Biology

Journal of Glycomics & Lipidomics

Author(s): Georg Nickenig

Abstract Share this page

Coronary heart disease (CHD) resulting from atherosclerosis is the single largest killer in the Western world. Approximately 40% of patients with hypertension have hypercholesterolemia, which is central to the pathogenesis of atherosclerosis and cardiovascular disease (CVD).1 Conversely, hypertension is a significant risk factor in patients with elevated cholesterol.2 There is strong synergy between hypertension and hypercholesterolemia in terms of risk factors for the development of CVD.2 Both hypertension and hypercholesterolemia result in endothelial dysfunction and consequently the development of atherosclerosis. The recent definition of the metabolic syndrome, characterized by hypertension, elevated cholesterol and triglyceride levels, insulin resistance/dyslipidemia, and central obesity, has brought together these conditions with the notion that they are linked and represent a cluster of factors that are synergistic for CVD.3

This article was published in Circulation and referenced in Journal of Glycomics & Lipidomics

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version